Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.

In the News

Feb 17

Written By Christine Mackenzie

Christine Mackenzie

Scaling CRISPR For Rare Disease With Aurora Therapeutics' Dr. Edward Kaye

Biotech CEOs discuss the state of the industry, what is needed to compete globally, the importance of having a patient-centric approach, and more